It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Clostridioides difficile (C. difficile) is an opportunistic anaerobic bacterium that causes severe diseases of the digestive tract of humans and animals. One of the possible methods of preventing C. difficile infection is to develop a vaccine. The most promising candidates for vaccine antigens are the proteins involved in the adhesion phenomena. Among them, the FliC and FliD are considered to be suitable candidates. In this paper, the FliC and FliD protein polypeptide epitopes were mapped in silico and by using PEPSCAN procedure. We identified four promising epitopes: 117QRMRTLS123, 205MSKAG209 of FliC and 226NKVAS230, 306TTKKPKD312 of FliD protein. We showed that 117QRMRTLS123 sequence is not only located in TLR5-binding and activating region, as previously shown, but forms an epitope recognized by C. difficile-infected patients’ antibodies. 205MSKAG209 is a C. difficile-unique, immunogenic sequence that forms an exposed epitope on the polymerized flagella structure which makes it a suitable vaccine antigen. 226NKVAS230 and 306TTKKPKD312 are well exposed and possess potential protective properties according to VaxiJen analysis. Our results open the possibility to use these epitopes as suitable anti-C. difficile vaccine antigens.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hirszfeld Institute of Immunology and Experimental Therapy, PAS, Laboratory of Immunobiology of Microbiome, Wroclaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
2 Hirszfeld Institute of Immunology and Experimental Therapy, PAS, Laboratory of Medical Microbiology, Wroclaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
3 Hirszfeld Institute of Immunology and Experimental Therapy, PAS, Laboratory of Genomics and Bioinformatics, Wroclaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
4 Wroclaw Medical University, Division of Angiology, Wroclaw, Poland (GRID:grid.4495.c) (ISNI:0000 0001 1090 049X); 4th Military Hospital in Wroclaw, Department of Internal Medicine, Wroclaw, Poland (GRID:grid.4495.c)